---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-26-016724"
form_type: "8-K"
ticker: "TLPH"
cik: "0001427925"
company_name: "TALPHERA, INC."
filed_at: "2026-05-13T20:10:24+00:00"
generated_at: "2026-05-13T22:05:22.601673+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Talphera Q1 net loss $2.6M; NEPHRO CRRT study enrollment progressing

## Summary
- Net loss of $2.6M ($0.04 per share) in Q1 2026, flat vs Q1 2025.
- Cash and investments $21.1M as of March 31, 2026.
- Combined R&D and SG&A expenses $3.9M, up from $2.9M YoY due to higher Niyad development costs.
- NEPHRO CRRT study enrollment exceeded 50% milestone; completion expected in 2026.
- Closed $4.1M third tranche of private placement upon hitting 35-patient enrollment milestone.

## SEC filing metadata
- accession: 0001437749-26-016724
- form_type: 8-K
- ticker: TLPH
- cik: 0001427925
- company_name: TALPHERA, INC.
- filed_at: 2026-05-13T20:10:24+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1427925/000143774926016724/0001437749-26-016724-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1427925/000143774926016724/acrx20260511_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-26-016724
- JSON: https://secwatch.observer/filing/0001437749-26-016724.json
- Plain text: https://secwatch.observer/filing/0001437749-26-016724.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.